RBC Capital lowered the firm’s price target on Bio-Techne (TECH) to $63 from $72 and keeps a Sector Perform rating on the shares. The company reported a 5c beat in Q3 driven by margin outperformance, and painted a much brighter picture of the near-term outlook in LST end-markets than peers, the analyst tells investors in a research note. RBC adds however that navigating the current NIH and tariff environment will be key in de-risking FY26 numbers.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne price target lowered to $60 from $75 at Stifel
- Bio-Techne Reports Strong Q3 2025 Revenue Growth
- Bio-Techne’s Earnings Call: Growth Amid Challenges
- Bio-Techne announces $500M share repurchase program
- Bio-Techne’s Resilience and Strong Financial Performance Justify Buy Rating Amid Market Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue